knowledge -WSS

knowledge

author：entertainment 2025-09-27 09:58:23 - browse：2629

Pfizer and Moderna aren’t the only vaccine money-makers. Much of the revenue and profits from Covid-19 vaccines are flowing behind the scenes, going to the contract manufacturers and clinical-trial organizers that turn the shots from lab-bench theory to mass-produced reality.

Both AstraZeneca and Johnson & Johnson publicly committed to not profiting off their products during the pandemic — though AstraZeneca has reserved the right to declare the pandemic over on July 1, even if the World Health Organization has not. Pfizer and Moderna made no such pledge, with Pfizer expected to make $15 billion in vaccine-related revenue this year, while Moderna is forecasting $18.4 billion in vaccine sales.

Contractors hired to test and manufacture these vaccines have enjoyed a share of the profits without the same level of public scrutiny.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Harvard's Jason Buenrostro wins MacArthur grant for genetics work

focus

WSS

Why a market frenzy over new weight loss drugs defies logic

FDA clears Verve to begin U.S. study of gene

UHS says company favors patients whose insurance pays more

The haunting brain science of long Covid

How AI can help patients find reliable information about doctors

Rise in cancer among younger people worries and puzzles doctors

leisure time

knowledge

knowledge

Jerome Adams on the need for new antivirals for Covid

Senate panel puts off hardest PBM reforms for another day

DIEP, the 'gold standard' of breast reconstruction, is under threat

Merck, Daiichi strike cancer drug pact worth up to $22 billion

DIEP, the 'gold standard' of breast reconstruction, is under threat

Roivant's CEO is a star, but biotech's black hole persists

Walensky prepares to leave CDC — and Congress — behind

Device maker Teleflex to acquire urology company for $600M

Wildfire smoke exposes gaps in outdoor worker protections

Why a market frenzy over new weight loss drugs defies logic

focus

STAT Summit: Meghan O’Rourke on making chronic illness visible

Roche drug slashes death risk in early

STAT Summit: The economic case for universal basic health care

Why a market frenzy over new weight loss drugs defies logic

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Why patients can’t get everything they want on drug pricing

knowledge

focus

focus

hotspot